Amendments to the Claims

The listing of claims will replace all prior versions, and listings, of claims in the application:

Claim Listing

1. (Currently amended) A method for enhancing the effect of a vaccine, the method comprising administering to a patient in need thereof, a vaccine ~~pharmaceutical~~ composition comprising pharmaceutically acceptable particles, the particles comprising

~~(i)~~ a biologically active agent that generates a protective immune response in an animal to which it is administered; in combination with

~~(ii)~~ ~~a~~ an ~~first~~ adjuvant chemical which increases the effect of the biologically active agent, said adjuvant chemical ~~selected from one or more~~ being selected from the group consisting of:

A) polyornithine,

B) a water soluble vitamin or water soluble vitamin derivative,

C) a positively charged cationic block copolymer or a positively charged cationic surfactant,

D) a clathrate,

E) a complexing agent,

F) cetrimides,

G) an S-layer protein, or

H) Methyl-glucamine; ~~and~~

~~(iii) a pharmaceutically acceptable carrier or diluent;~~ subject to the following provisos

a) ~~when the chemical (ii) above is selected from D) or E), the biologically active agent is an agent that generates a protective immune response in an animal to which it is administered;~~

~~b)~~ when the adjuvant chemical ~~(ii)~~ ~~above~~ is selected from A) ~~and the biologically active agent is an agent that generates a protective immune~~

~~response in an animal to which it is administered~~, the composition is for administration to a mucosal surface,

~~c)~~ b) when the adjuvant chemical ~~(ii) above~~ is selected from C) ~~and the biologically active agent is an agent that generates a protective immune response in an animal to which it is administered~~, the composition does not contain a polyacrylic acid, and

~~d)~~ c) when the adjuvant chemical ~~(ii) above~~ is selected from G) ~~and the biologically active agent is an agent that generates a protective immune response in an animal to which it is administered~~, the ~~carrier or diluent of (iii)~~ particle is a microsphere or liposome.

Claim 2 (Cancelled)

3. (Currently amended) The ~~composition~~ method of claim 1 wherein the adjuvant chemical acts as an immunostimulant.

4. (Currently amended) The ~~composition~~ method of claim 1 wherein the ~~said~~ adjuvant chemical is selected from one or more of;

A) ~~the poly-ornithine~~ polyornithine ~~has~~ having a molecular weight from 5 to 150kDa;

B) ~~the water-soluble vitamin or water-soluble vitamin derivative is~~ vitamin E TPGS (d-alpha tocophenyl polyethylene glycol 1000 succinate),

C) ~~the~~ a cationic block copolymer or ~~the~~ a cationic surfactant, ~~is~~ positively charged by means of NH_2^+ groups

D) ~~the~~ a complexing agent that forms complexes with fatty acids, or

E) ~~the clathrate is a~~ cyclodextrin or a derivative thereof.

5. (Cancelled)

6. (Currently amended) The ~~composition~~ method of claim ~~5~~ 1 wherein the ~~particle is a microsphere or liposome~~ particles are microspheres or liposomes.

7. (Currently amended) The ~~composition~~ method of claim 6 ~~which comprises a microsphere~~ wherein the particles are microspheres.

8. (Currently amended) The ~~composition~~ method of claim 7 wherein the ~~microsphere is~~ microspheres are prepared using a high molecular weight polymer.

9. (Currently amended) The ~~composition~~ method of claim 8 wherein the polymer has a molecular weight of 100kDa or more.

10. (Currently amended) The ~~composition~~ method of claim 7 wherein the microsphere comprises poly-(L-lactide).

Claim 11 (Cancelled)

12. (Currently amended) The ~~composition~~ method of claim 1 ~~which~~ wherein the vaccine composition is administered to a mucosal surface of the animal or administered parenterally to the animal.

13. (Currently amended) The ~~composition~~ method of claim 1 ~~2~~ ~~which~~ wherein the vaccine composition further comprises a second adjuvant.

Claims 14-25 (Withdrawn)

26. (Currently amended) The ~~composition~~ method of claim ~~4~~ 30 wherein

~~A)~~ the complexing agent forms complexes with deoxycholic acid~~; or~~

~~B) the clathrate is dimethyl-β-cyclodextrin~~ .

27. (New) The method of claim 1 wherein the adjuvant chemical is A) polyornithine having a molecular weight from 5 to 150 kDa.

28 (New) The method of claim 1 wherein the adjuvant chemical is B) a water soluble vitamin or water soluble vitamin derivative comprising vitamin E TPGS (d-alpha tocophenyl polyethylene glycol 1000 succinate).

29. (New) The method of claim 1 wherein the adjuvant chemical is C) a cationic block copolymer or a cationic surfactant, positively charged by means of NH_2^+ groups.

30. (New) The method of claim 1 wherein the adjuvant chemical is E) a complexing agent that forms complexes with fatty acids.